PTC Therapeutics Inc
NASDAQ:PTCT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
18.07
42.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PTCT stock under the Base Case scenario is 45.38 USD. Compared to the current market price of 40.69 USD, PTC Therapeutics Inc is Undervalued by 10%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
PTC Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PTCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
PTC Therapeutics Inc
Balance Sheet Decomposition
PTC Therapeutics Inc
Current Assets | 1.4B |
Cash & Short-Term Investments | 1.1B |
Receivables | 187.2m |
Other Current Assets | 77.5m |
Non-Current Assets | 558.4m |
PP&E | 123.1m |
Intangibles | 412.2m |
Other Non-Current Assets | 23.1m |
Current Liabilities | 609.8m |
Accounts Payable | 128.6m |
Accrued Liabilities | 86.7m |
Other Current Liabilities | 394.6m |
Non-Current Liabilities | 2.3B |
Long-Term Debt | 2.1B |
Other Non-Current Liabilities | 156.5m |
Earnings Waterfall
PTC Therapeutics Inc
Revenue
|
900.5m
USD
|
Cost of Revenue
|
-68.9m
USD
|
Gross Profit
|
831.6m
USD
|
Operating Expenses
|
-1B
USD
|
Operating Income
|
-196.3m
USD
|
Other Expenses
|
-283.3m
USD
|
Net Income
|
-479.5m
USD
|
Free Cash Flow Analysis
PTC Therapeutics Inc
USD | |
Free Cash Flow | USD |
PTC Therapeutics reported strong performance in Q2 2024, with revenue hitting $187 million, anchored by $118 million from their Duchenne Muscular Dystrophy (DMD) franchise. This consistent success led the company to revise their 2024 revenue guidance to between $700 million and $750 million. The sale of their gene therapy manufacturing business generated $27.5 million in upfront cash, allowing further strategic financial maneuvers. PTC's global plans include the planned 2025 launch of sepiapterin for PKU, supported by strong clinical data, and the continued advancement of therapies for Huntington's disease, Friedreich ataxia, and ALS.
What is Earnings Call?
PTCT Profitability Score
Profitability Due Diligence
PTC Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
PTC Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
PTCT Solvency Score
Solvency Due Diligence
PTC Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
PTC Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PTCT Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PTCT is 40.96 USD with a low forecast of 26.26 USD and a high forecast of 67.2 USD.
Dividends
Current shareholder yield for PTCT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PTCT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.
Contact
IPO
Employees
Officers
The intrinsic value of one PTCT stock under the Base Case scenario is 45.38 USD.
Compared to the current market price of 40.69 USD, PTC Therapeutics Inc is Undervalued by 10%.